Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm signs antibacterial, antifungal drug development deal with Merck with $100 million-plus potential for each target.
You may also be interested in...
Analysts See Daiichi Sankyo Exercising Light Control Over Ranbaxy
Parallels to Novartis-Sandoz 2005 combination seen.
Analysts See Daiichi Sankyo Exercising Light Control Over Ranbaxy
Parallels to Novartis-Sandoz 2005 combination seen.
Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation
Deal demonstrates strength of AstraZeneca’s patents, analyst says.